首页> 外国专利> EYE DISEASE TREATMENT AGENT, SCREENING METHOD THEREOF, OR PREDICTION METHOD OF REJECTION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION

EYE DISEASE TREATMENT AGENT, SCREENING METHOD THEREOF, OR PREDICTION METHOD OF REJECTION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION

机译:视网膜色素上皮细胞移植相关的眼病治疗剂,其筛查方法或预测排斥方法

摘要

To provide eye disease therapeutic agents and screening methods for eye disease therapeutic agents, and the like, and also to provide prediction methods of rejection associated with retinal pigment epithelial cell transplantation into patients with eye diseases.SOLUTION: Provided is an eye disease treatment agent and the like for an eye disease patient in which at least one allele at a corresponding locus has a combination that matches the allele at the locus of a retinal pigment epithelial cell, the agent containing the retinal pigment epithelial cell in which the gene type in HLA-A locus, HLA-B locus and HLA-DR locus is homozygous respectively.SELECTED DRAWING: None
机译:提供眼病治疗剂和用于眼病治疗剂的筛选方法等,并提供与视网膜色素上皮细胞移植入眼病患者相关的排斥反应的预测方法。对于眼病患者而言,例如在相应位点的至少一个等位基因具有与视网膜色素上皮细胞的所在地等位基因相匹配的组合,该药剂包含视网膜色素上皮细胞,其中HLA-一个基因座,HLA-B基因座和HLA-DR基因座分别是纯合的。

著录项

  • 公开/公告号JP2020055796A

    专利类型

  • 公开/公告日2020-04-09

    原文格式PDF

  • 申请/专利权人 DAINIPPON SUMITOMO PHARMA CO LTD;

    申请/专利号JP20190154627

  • 发明设计人 TAKAHASHI MASAYO;SUGITA SUNAO;

    申请日2019-08-27

  • 分类号A61K35/30;A61K35/545;A61K45;A61P27/02;A61L27/36;A61L27/38;A61L27/40;C12Q1/6827;C12Q1/04;C12N5/10;C12N15/12;G01N33/50;G01N33/15;G01N33/68;

  • 国家 JP

  • 入库时间 2022-08-21 11:36:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号